Literature DB >> 12877384

Methylated DNA as a possible screening marker for neoplastic disease in several body fluids.

Hannes M Müller1, Martin Widschwendter.   

Abstract

Early detection appears to be one of the most important approaches to reducing mortality caused by neoplasia. Changes in DNA methylation have been recognized as one of the most common molecular alterations in human tumors. Due to the ubiquity of DNA methylation changes and the possibility to detect methylated DNA in several body fluids, this specifically altered DNA may serve as a potential new screening marker for neoplastic disease.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12877384     DOI： 10.1586/14737159.3.4.443

Source DB:  PubMed          Journal:  Expert Rev Mol Diagn        ISSN： 1473-7159            Impact factor:   5.225


  13 in total

Review 1.  DNA methylation and microRNA biomarkers for noninvasive detection of gastric and colorectal cancer.

Authors:  Yuji Toiyama; Yoshinaga Okugawa; Ajay Goel
Journal:  Biochem Biophys Res Commun       Date:  2014-08-13       Impact factor: 3.575

2.  Detection and quantification of mutations in the plasma of patients with colorectal tumors.

Authors:  Frank Diehl; Meng Li; Devin Dressman; Yiping He; Dong Shen; Steve Szabo; Luis A Diaz; Steven N Goodman; Kerstin A David; Hartmut Juhl; Kenneth W Kinzler; Bert Vogelstein
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-28       Impact factor: 11.205

3.  Epigenetic Signatures in Breast Cancer: Clinical Perspective.

Authors:  Paola Parrella
Journal:  Breast Care (Basel)       Date:  2010-04-23       Impact factor: 2.860

Review 4.  Epigenetic diagnostics of cancer--the application of DNA methylation markers.

Authors:  Jaroslaw Paluszczak; Wanda Baer-Dubowska
Journal:  J Appl Genet       Date:  2006       Impact factor: 3.240

5.  Methylated genes in breast cancer: associations with clinical and histopathological features in a familial breast cancer cohort.

Authors:  Theresa Swift-Scanlan; Russell Vang; Amanda Blackford; Mary Jo Fackler; Saraswati Sukumar
Journal:  Cancer Biol Ther       Date:  2011-05-15       Impact factor: 4.742

6.  Control of carry-over contamination for PCR-based DNA methylation quantification using bisulfite treated DNA.

Authors:  Reimo Tetzner; Dimo Dietrich; Juergen Distler
Journal:  Nucleic Acids Res       Date:  2006-11-28       Impact factor: 16.971

7.  Improved amplification efficiency on stool samples by addition of spermidine and its use for non-invasive detection of colorectal cancer.

Authors:  Jean-Pierre Roperch; Karim Benzekri; Hicham Mansour; Roberto Incitti
Journal:  BMC Biotechnol       Date:  2015-05-29       Impact factor: 2.563

8.  Genome-scale discovery of DNA-methylation biomarkers for blood-based detection of colorectal cancer.

Authors:  Christopher P E Lange; Mihaela Campan; Toshinori Hinoue; Roderick F Schmitz; Andrea E van der Meulen-de Jong; Hilde Slingerland; Peter J M J Kok; Cornelis M van Dijk; Daniel J Weisenberger; Hui Shen; Robertus A E M Tollenaar; Peter W Laird
Journal:  PLoS One       Date:  2012-11-28       Impact factor: 3.240

9.  MeCP2 and MBD2 expression in human neoplastic and non-neoplastic breast tissue and its association with oestrogen receptor status.

Authors:  H M Müller; H Fiegl; G Goebel; M M Hubalek; A Widschwendter; E Müller-Holzner; C Marth; M Widschwendter
Journal:  Br J Cancer       Date:  2003-11-17       Impact factor: 7.640

10.  Aberrant methylation of NPY, PENK, and WIF1 as a promising marker for blood-based diagnosis of colorectal cancer.

Authors:  Jean-Pierre Roperch; Roberto Incitti; Solène Forbin; Floriane Bard; Hicham Mansour; Farida Mesli; Isabelle Baumgaertner; Francesco Brunetti; Iradj Sobhani
Journal:  BMC Cancer       Date:  2013-12-01       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.